Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
October 27 2022 - 4:30PM
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the
“Company”) (NASDAQ: DYAI), a global biotechnology company focused
on building innovative microbial platforms to address the growing
demand for global protein production and unmet clinical needs for
effective and affordable biopharmaceutical products for human and
animal health, today announced that it will report its financial
results for the third quarter 2022 and host a corporate update
conference call on Thursday, November 10, 2022.
Conference Call Information
Date: Thursday, November 10, 2022
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 877-407-0784;
International +1-201-689-8560
Conference ID: 13731917
Webcast Link:
https://viavid.webcasts.com/starthere.jsp?ei=1561607&tp_key=84d3d19ead.
An archive of the webcast will be available within 24 hours after
completion of the live event and will be accessible on the Investor
Relations section of the Company's website at www.dyadic.com.
To access the replay of the webcast, please follow the webcast link
above.
If you have any questions that you would like to
ask management during the Q&A session, please email
hzosiak@dyadic.com prior to the conference call.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company committed to building disruptive microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products for human and animal
health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable fungus
Thermothelomyces heterothallica (formerly Myceliophthora
thermophila). Our lead technology, C1-cell protein production
platform, is based on an industrially proven microorganism (named
C1), which is currently used to speed development, lower production
costs, and improve performance of biologic vaccines and drugs at
flexible commercial scales for the human and animal health markets.
Dyadic has also developed the Dapibus™ filamentous fungal
based microbial protein production platform to enable the rapid
development and large-scale manufacture of low-cost proteins,
metabolites, and other biologic products for use in
non-pharmaceutical applications, such as food, nutrition, and
wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please visit
http://www.dyadic.com.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of our clinical
trial application and our ability to secure commercial agreements
and take advantage of other business opportunities. Actual events
or results may differ materially from those in the forward-looking
statements because of various important factors, including those
described in the Company’s most recent filings with the SEC. Dyadic
assumes no obligation to update publicly any such forward-looking
statements, whether because of new information, future events or
otherwise. For a more complete description of the risks that could
cause our actual results to differ from our current expectations,
please see the section entitled “Risk Factors” in Dyadic’s annual
reports on Form 10-K and quarterly reports on Form 10-Q filed with
the SEC, as such factors may be updated from time to time in
Dyadic’s periodic filings with the SEC, which are accessible on the
SEC’s website and at http://www.dyadic.com.
Contact:
Dyadic International, Inc.Ping W. RawsonChief
Financial OfficerPhone: (561) 743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024